A new modelling study reveals that only 7% of carbapenem-resistant Gram-negative (CRGN) bacterial infections in eight LMICs ...

The FDA delivered a blow to Spero's hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.

Resistance to carbapenems in Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, mainly determined by the production of carbapenem-hydrolyzing β-lactamases, has emerged ...